2021
Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC).
Chehrazi-Raffle A, Meza L, Alcantara M, Salgia N, Dizman N, Bergerot P, Hsu J, Kortylewski M, Pal S. Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 352-352. DOI: 10.1200/jco.2021.39.6_suppl.352.Peer-Reviewed Original ResearchVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaImmune checkpoint inhibitorsPlasma cytokinesClinical benefitCommon immune checkpoint inhibitorsICI combination therapyLow pretreatment levelsRenal cell carcinomaEligible patientsICI armsStable diseaseCheckpoint inhibitorsImmunologic profilePartial responseSystemic therapyComplete responseProspective studyIL-1raCell carcinomaCombination therapyIL-6Pretreatment levelsDistinct cytokinesG-CSF
2018
Long-Term Use of GLP-1 Receptor Agonists Alter GLP-1 Receptor mRNA Expression in Hindbrain Pathways That Regulate Gastric Motility in Mice
WANG P, MAMILLAPALLI R, ZHU W, CHAN O. Long-Term Use of GLP-1 Receptor Agonists Alter GLP-1 Receptor mRNA Expression in Hindbrain Pathways That Regulate Gastric Motility in Mice. Diabetes 2018, 67 DOI: 10.2337/db18-1088-p.Peer-Reviewed Original ResearchGLP-1R expressionGLP-1R mRNA expressionGastric motilityGLP-1RAsMRNA expressionGLP-1 receptor mRNA expressionSuppressive effectGLP-1 receptor agonistsPost-prandial glucose levelsType 2 diabetesReceptor mRNA expressionAdeno-associated viral vectorLong-term useHindbrain pathwaysIncretin systemSolitary tractGlucagon releaseReceptor agonistC57BL6 micePretreatment levelsGLP-1RGlucose levelsTherapeutic strategiesReceptor desensitizationGLP-1R.
2015
Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity
Doherty LF, Taylor HS. Leiomyoma-derived transforming growth factor-β impairs bone morphogenetic protein-2-mediated endometrial receptivity. Fertility And Sterility 2015, 103: 845-852. PMID: 25596622, PMCID: PMC4363085, DOI: 10.1016/j.fertnstert.2014.12.099.Peer-Reviewed Original ResearchConceptsEndometrial stromal cellsLeukemia inhibitory factorEndometrial receptivityTGF receptorElevated TGF-β levelsCultured endometrial stromal cellsTGF-β receptor type IITGF-β antibodyTGF-β levelsReceptor type 1aReceptor type IIBMP receptor type 1AEnzyme-linked immunosorbentRecombinant human BMP-2LIF expressionSymptomatic leiomyomasPregnancy lossSurgical specimensPretreatment levelsUterine leiomyomaReceptor type 1BMAIN OUTCOMELeiomyoma cellsLeiomyomaHuman BMP-2
2011
Maintenance of Quality of Life Improvements in Diverse Rural Older Adults
Scogin F, Morthland M, Kaufman A, Chaplin W, Kong G. Maintenance of Quality of Life Improvements in Diverse Rural Older Adults. Psychology And Aging 2011, 26: 475-479. PMID: 21417535, PMCID: PMC3222293, DOI: 10.1037/a0022130.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyOlder adultsDiverse Rural Older AdultsSix-month followEvidence-based treatmentsQuality of lifeMaintenance of effectsRural older adultsPretreatment levelsPosttreatment gainsPsychological symptomsDisadvantaged sampleMaintenance of qualityTreatment effectsLife improvementAfrican AmericansFollowAdultsParticipantsTherapySymptoms
2008
Examination of Predictors and Moderators for Self-Help Treatments of Binge-Eating Disorder
Masheb RM, Grilo CM. Examination of Predictors and Moderators for Self-Help Treatments of Binge-Eating Disorder. Journal Of Consulting And Clinical Psychology 2008, 76: 900-904. PMID: 18837607, PMCID: PMC2596590, DOI: 10.1037/a0012917.Peer-Reviewed Original ResearchConceptsBinge-eating disorderSelf-help treatmentTreatment outcomesDisorder psychopathologyRespective pretreatment levelsPersonality disorderPersonality disorder comorbidityRandomized clinical trialsMajor depressive disorderModerators of outcomeBinge Eating DisorderNegative affectBED onsetBinge remissionOverweight patientsClinical characteristicsPoor prognosisPrognostic significanceClinical trialsDepressive disorderPretreatment levelsDimensional outcomesDisorder comorbidityPatientsDisorders
2003
Cognitive–Behavioral Therapy for Chronic Low Back Pain in Older Persons: A Preliminary Study
Reid MC, Otis J, Barry LC, Kerns RD. Cognitive–Behavioral Therapy for Chronic Low Back Pain in Older Persons: A Preliminary Study. Pain Medicine 2003, 4: 223-230. PMID: 12974821, DOI: 10.1046/j.1526-4637.2003.03030.x.Peer-Reviewed Original ResearchConceptsChronic low back painCognitive behavioral therapyLow back painPain intensityOlder personsBack painParticipants' pain intensityPain-related disabilityPain-related disability scoresUncontrolled pilot studyWeekly individual sessionsSocial activity levelsDisability scoresMean agePretreatment levelsFeasible treatmentTreatment sessionsPosttreatment assessmentPotential efficacyBehavioral therapyPilot studyWeeksMean numberActivity levelsPain
1998
Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors.
Trauner M, Arrese M, Lee H, Boyer J, Karpen S. Endotoxin downregulates rat hepatic ntcp gene expression via decreased activity of critical transcription factors. Journal Of Clinical Investigation 1998, 101: 2092-2100. PMID: 9593765, PMCID: PMC508797, DOI: 10.1172/jci1680.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Acids and SaltsCarrier ProteinsCells, CulturedCholestasisDNA-Binding ProteinsDown-RegulationEndotoxinsGene Expression RegulationHepatocyte Nuclear Factor 1Hepatocyte Nuclear Factor 1-alphaHepatocyte Nuclear Factor 1-betaLiverMaleMembrane Transport ProteinsNuclear ProteinsOrganic Anion Transporters, Sodium-DependentPromoter Regions, GeneticRatsRats, Sprague-DawleyRNA, MessengerSepsisSymportersTranscription FactorsConceptsNuclear binding activityNtcp mRNA levelsMRNA levelsHepatobiliary transportersMRNA expressionCritical transcription factorTime pointsSepsis-associated cholestasisNuclear factor-kappaBSodium-dependent uptakeEffector cytokinesSequential time pointsEndotoxin administrationPretreatment levelsBinding activityMaximal decreaseBile acidsFactor-kappaBHepatocyte nuclear factor 1Normal levelsHepatic basolateral membraneNuclear factorMarked reductionCoordinated downregulationEndotoxin
1996
Outcome of intensive inpatient treatment for combat-related posttraumatic stress disorder
Johnson D, Rosenheck R, Fontana A, Lubin H, Charney D, Southwick S. Outcome of intensive inpatient treatment for combat-related posttraumatic stress disorder. American Journal Of Psychiatry 1996, 153: 771-777. PMID: 8633688, DOI: 10.1176/ajp.153.6.771.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultCombat DisordersCombined Modality TherapyFollow-Up StudiesHospital UnitsHospitalizationHospitals, VeteransHumansInterpersonal RelationsMaleMilieu TherapyMoralePersonality InventoryProgram EvaluationPsychiatric Status Rating ScalesSocial AdjustmentTreatment OutcomeUnited StatesVeteransVietnamConceptsPosttraumatic stress disorderCombat-related posttraumatic stress disorderIntensive inpatient treatmentInpatient treatmentStress disorderIntensive inpatient programOverall study groupLength of stayLong-term intensive inpatient treatmentForm of treatmentVietnam veteransInpatient treatment programPatient characteristicsPatient evaluationPretreatment levelsInpatient programChronic natureStudy groupPsychiatric symptomsMale veteransRehabilitation focusTreatment programSymptomsSocial functioningAdmission
1991
Short report: plasma aluminium concentration and 24‐hour urinary aluminium excretion before, during and after treatment with sucralfate
MISTRY P, VARGHESE Z, POUNDER RE. Short report: plasma aluminium concentration and 24‐hour urinary aluminium excretion before, during and after treatment with sucralfate. Alimentary Pharmacology & Therapeutics 1991, 5: 549-553. PMID: 1793786, DOI: 10.1111/j.1365-2036.1991.tb00524.x.Peer-Reviewed Original ResearchConceptsUrinary aluminium excretionPlasma aluminum concentrationAluminium excretionNormal renal functionCessation of treatmentWeeks of treatmentSucralfate q.Renal functionDyspeptic patientsUrinary excretionStandard treatmentPretreatment levelsSucralfateTissue accumulationExcretionSignificant riseWeeksTreatmentSignificant increaseMicrogramsPatients
1988
Tourette's Syndrome: Clinical and Neurochemical Correlates
RIDDLE M, LECKMAN J, ANDERSON G, ORT S, HARDIN M, STEVENSON J, COHEN D. Tourette's Syndrome: Clinical and Neurochemical Correlates. Journal Of The American Academy Of Child & Adolescent Psychiatry 1988, 27: 409-412. PMID: 3182595, DOI: 10.1097/00004583-198807000-00004.Peer-Reviewed Original ResearchConceptsTourette Syndrome Global ScalePHVA levelsTourette syndromeTS patientsLower CSF HVA levelsPlasma homovanillic acid levelsSimple motor ticsHomovanillic acid levelsCSF HVA levelsSignificant inverse correlationHVA levelsMotor restlessnessMotor ticsPretreatment levelsTotal symptomsNeurochemical correlatesTreatment responsePlasma 3Control groupPatientsSyndromeAcid levelsInverse correlationSignificant correlationIndividual items
1987
Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation
Braverman I, Klein S, Grant A. Electron microscopic and immunolabeling studies of the lesional and normal skin of patients with mycosis fungoides treated by total body electron beam irradiation. Journal Of The American Academy Of Dermatology 1987, 16: 61-74. PMID: 3100584, DOI: 10.1016/s0190-9622(87)70005-x.Peer-Reviewed Original ResearchConceptsEpidermal Langerhans cellsElectron beam therapyLangerhans cellsMycosis fungoidesIndeterminate cellsNormal skinDisease courseLesional skinBeam therapySkin lesionsNonspecific skin lesionsPatient's disease courseIa-positive cellsEpidermal cell suspensionsEpidermal thymocyteClinical remissionBiopsy specimensPretreatment levelsIa antigensFungoidesTherapyLesionsSkinPatientsCells
1979
Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply